Merck/Aetna Pact Links Januvia Value-Based Payment To Treatment Intensification
Merck will use the need for added therapies as a measure to determine rebate value – one that might be more straightforward than monitoring hemoglobin A1C data.
You may also be interested in...
US payers and drug companies are showing interest in outcomes-based contracts and even implementing some but whether they will become the reimbursement arrangements of the future remains highly uncertain.
The promise of outcomes-based contracts for biopharmaceuticals has yet to be realized in the US. Although precise numbers are hard to come by, payers and manufacturers agree the field is still nascent. However, they don’t seem to be giving up on the idea.
Leaders from across the industry met at Informa's Pharmaceutical Strategy conference and addressed some of the most critical issues facing the industry: pharma's tarnished reputation and drug pricing.